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James R. Rigas, MD, and Karen Kelly, MDyAbstract: Locally advanced non-small cell lung cancer (NSCLC)
is a multifaceted disease that is challenging to manage. The majority
of patients can be appropriately treated with a combination of
chemotherapy and radiation therapy; however, a subset of stage
III patients who are considered surgical candidates may require a
modification of this plan. For example, a trimodal approach using
chemoradiation followed by surgery may be beneficial for fit patients
with bulky mediastinal disease who are candidates for lobectomy,
whereas patients with minimal mediastinal nodal involvement may
receive only chemotherapy before surgical resection. No standard
chemotherapy exists for this group of stage IIIA resectable patients.
Phase II data from studies employing neoadjuvant cisplatin
combinations suggest that these regimens are active and well toler-
ated. For patients with unresectable stage III NSCLC, concurrent
chemoradiation is the standard of care at the present time for patients
with good performance status, good pulmonary function tests, and an
acceptable volume of normal lung receiving 20 Gy (V20). To manage
distant micrometastasis further, induction and consolidation regi-
mens are under investigation during which full-dose chemotherapy is
administered either before (as induction) or after (as consolidation)
concurrent chemoradiotherapy. To date, consolidation docetaxel
after concurrent etoposide, cisplatin and thoracic radiation has shown
encouraging survival results in a large Southwest Oncology Group
phase II trial. This article will review the current treatment strategies
for stage III NSCLC.
Key Words: Non-small cell lung cancer, Chemotherapy,
Radiotherapy, Docetaxel, Cisplatin, Etoposide, Consolidation.
(J Thorac Oncol. 2007; suppl. 2: S77–S85)INTRODUCTION
Approximately one-third of patients with non-small celllung cancer (NSCLC) are diagnosed with locally
advanced (stage III) disease.1 Five clinically distinct subsets
exist within stage III disease, which accounts for the
heterogeneity of this population as well as the number of
treatment options available (Table 1). At the extremes
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ology * Volume 2, Number 6, Supplemenplatinum-based chemotherapy,2,3 whereas stage IIIB with
pathologically confirmed involvement of the pleura
(T4, pleural effusion) is synonymous with advanced disease
and is best managed with palliative therapy. For the
remainder of patients, who have potentially curable disease,
treatment goals include local tumor control and eradication
of distant micrometastases, while minimizing adverse
events. Treatment options of chemotherapy or radiation
may differ among the clinically distinct stage III subsets.
Potentially resectable disease remains the most controver-
sial area, but optimal treatment strategies for unresectable
stage III disease also remain to be defined.
In both stage IIIA and IIIB disease, research to date
has shown benefits for combined modality therapy with
chemotherapy, radiation,4 or surgery, or both, for pro-
perly chosen candidates. Whereas platinum-based doublets
remain the standard regimen, the choice of the complemen-
tary agent remains a subject of investigation. Over the past
decade, agents under consideration for platinum-based
doublets include docetaxel, paclitaxel, irinotecan, vinorel-
bine, and gemcitabine. Of these agents, the taxanes have
been the most extensively studied. Mechanistically, taxanes
induce apoptosis independent of p53 in p53-disrupted cell
lines; a preclinical study further suggested that although
both paclitaxel and docetaxel induce p27, docetaxel is more
efficient than paclitaxel at phosphorylating Bcl2.5 Further-
more, docetaxel has shown activity in cisplatin-resistant and
paclitaxel-resistant NSCLC cell lines,6–8 has a higher
affinity to microtubulin and slower efflux from cytoplasm
than paclitaxel,9,10 and is a known radiosensitizer with
potential immunomodulating and antiangiogenic proper-
ties.11,12 In clinical studies, docetaxel has shown positive
results in platinum-pretreated NSCLC.13–15 Our most recent
investigations have attempted to incorporate the emerging
epidermal growth factor and vascular endothelial growth
factor receptor targeted therapies into the care of patients
with locally advanced NSCLC. This article will review new
directions in treating locally advanced NSCLC, and will
include recent studies for both resectable and unresectable
stage III NSCLC.
RESECTABLE STAGE III NON-SMALL CELL
LUNG CANCER
Historically, surgery or radiation were used alone for
treating potentially resectable stage IIIA NSCLC until
the 1990s, when two small randomized trials suggested
benefit from the incorporation of chemotherapy into theuthorized reproduction of this article is prohibited.
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TABLE 1. Clinically Distinct Subsets within Stage III Non-small Cell Lung Cancer.
Stage TNM Classification Description
Stage IIIA T3 N1 Peripheral lesion with chest wall invasion or tumor < 2 cm distal to carina
T1–3 N2 Prognosis and therapy defined by N2 status (ipsilateral mediastinal nodes)
Stage IIIB T1–4 N3 Prognosis and therapy largely defined by N3 disease (contralateral mediastinal,
supraclavicular nodes)
T4 N0–2 Locally invasive primary tumor (T4) and no malignant pleural effusion; no contralateral
or supraclavicular nodes
T4 N0–3 Malignant pleural effusion (T4)
TNM, tumor–node–metastasis.
Stage IIIA(N2) can be further subdivided according to the extent of nodal involvement (microscopic, minimal or bulky N2 disease) and planned surgical resection
(lobectomy versus pneumonectomy).
Rigas and Kelly Journal of Thoracic Oncology * Volume 2, Number 6, Supplement 2, June 2007treatment plan.16–18 Each trial evaluated the role of
induction (neoadjuvant) chemotherapy, and demonstrated
significantly prolonged median overall survival with the
addition of chemotherapy before surgery. Median survival
times were 26 months and 64 months with neoadjuvant
platinum-based regimens compared with 8 months and
11 months with surgery alone. Relapse rates were 52 and
74% without chemotherapy compared with 29 and 56%
with chemotherapy. These findings are further supported by
the results of a recent meta-analysis, which sought to
determine the effectiveness of neoadjuvant chemotherapy
compared with surgery alone in NSCLC.19 Data from seven
of 12 eligible randomized clinical trials were available,
yielding a hazard ratio of 0.82 for improved survival with
chemotherapy ( p¼ 0.02).20,21 Across all disease stages,
survival was increased from 14 to 20% at 5 years.
Phase II–III Trials of Neoadjuvant (Induction)
Chemotherapy
Several third-generation chemotherapy doublets have
been evaluated as neoadjuvant treatment for patients with
stage IIIA NSCLC in phase II trials (Table 2).22–29
Docetaxel, gemcitabine, and vinorelbine have all been
combined with cisplatin in this setting, each with encourag-
ing activity. Whereas the results appear generally consistent
among the trials, the longest median survival was reported
with a combination of docetaxel/cisplatin in the largest
trial.22,23 In that study conducted by the Swiss Institute for
Applied Cancer Research (SAKK) in patients with stage
IIIA(N2) disease, three cycles of docetaxel (85 mg/m2)
and cisplatin (80–100 mg/m2) were administered to
90 patients.22,23 Responding patients (n¼ 75, 83%) went
on to surgery (with subsequent radiotherapy in the event of
positive margins or involvement of the uppermost mediasti-
nal lymph node). The overall response rate to chemotherapy
was 66%, and pathological downstaging was achieved in
60% of surgical patients (Table 2). The median overall
survival for the intent-to-treat population was 28 months.
In patients undergoing surgery, the median survival was
35 months, and 36% of these patients were alive and disease-
free at 3 years. Of 51 patients (68%) who experienced
relapse or progression, two had local relapse only, six had
distant relapse only, and 43 had local and distant metastases.Copyright © Adis Data Information BV. Una
S78Grade 3/4 granulocytopenia occurred in 54% of patients;
grade 3 anemia and thrombocytopenia were very infrequent
(2 and 1% of patients, respectively). Postoperative mortality
was 3%. The SAKK continues to evaluate the docetaxel/
cisplatin combination in its phase III trial, SAKK 16/00
(Figure 1). A second trial, the intergroup RTOG0412/S0332,
designed to evaluate this regimen as neoadjuvant che-
motherapy compared with concurrent chemoradiation in
resectable stage IIIA(N2), has unfortunately recently closed
as a result of poor accrual.
The European Organization for Research and Treat-
ment of Cancer (EORTC) has evaluated several third-
generation combinations. In EORTC 08955, 47 eligible
stage IIIA(N2) patients received gemcitabine/cisplatin
chemotherapy.24 Of these, 35 were subsequently randomly
assigned into the EORTC 08941 trial30 to receive either
surgery or radiotherapy. The overall response rate was 70%
(Table 2). The median duration of survival for all enrolled
patients (n¼ 53) was 18.9 months. Relapse patterns were not
reported. Incidences of grades 3/4 hematological toxicities
were 38% neutropenia, 15% anemia, and 60% thrombocy-
topenia. In EORTC 08984, the response rate to docetaxel/
cisplatin was 45%, with a median survival of 15.8 months
(Table 2).25 The reasons for the seemingly poor results
observed in that study are not completely known. A larger
proportion of patients in the SAKK trial had performance
status 0 (60%) compared with those in EORTC 08984
(35%); however, a larger proportion of SAKK trial parti-
cipants had T3 tumors (33 versus 15%).22,23,25
Other trials evaluating the cisplatin/gemcitabine doublet
in patients with stage IIIA or IIIB NSCLC showed com-
parable response rates (62–64%) and median survival times
(17–24 months).27,28 Resection rates were low (35–48%).
Similarly, the combination of cisplatin and vinorelbine or
vinblastine demonstrated a 63% response rate, with a low
median survival time of a little more than 1 year.29 Less than
half the patients underwent resection (44%), with all
patients relapsing.
Phase II–III Trials of Neoadjuvant (Induction)
Chemoradiation
Building on induction or neoadjuvant chemotherapy
with concurrent radiation therapy is logical. Chemoradiationuthorized reproduction of this article is prohibited.
 2007 International Association for the Study of Lung Cancer
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Chemotherapy
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FIGURE 1. Study design of SAKK 16/00.22
Rigas and Kelly Journal of Thoracic Oncology * Volume 2, Number 6, Supplement 2, June 2007with docetaxel-platinum as neoadjuvant treatment shows
high activity, as evidenced by results of several trials
including a phase II study and an observational study of
patients treated by a single surgeon.26,31 The observational
study compared two non-randomized groups of patients
with stage IIIA(N2) or IIIB(N2) who received either
cisplatin 100 mg/m2–docetaxel 85 mg/m2 chemotherapy
alone (n¼ 36) or cisplatin-based chemotherapy with radio-
therapy (either cisplatin 100 mg/m2–docetaxel 85 mg/m2
followed by radiotherapy or cisplatin 60 mg/m2–vinblastine
6 mg/m2 concurrent with radiotherapy; n¼ 46).26 In the
chemoradiotherapy group, mediastinal downstaging (pN0/
pN1) was achieved in 78% (compared with 61% in the
chemotherapy group alone). The postoperative mortality
rate was 4%. With a median follow-up of 53 months,
16 patients (35%) had relapsed, 75% distantly. In the
chemotherapy only and chemoradiotherapy groups com-
bined, the 5-year survival rate was 40%, with no significant
difference between the two groups. In the phase II trial,
chemoradiotherapy was administered concurrently.31 Pa-
tients (n¼ 22) with stage IIIA(N2) or IIIB disease received
cisplatin 40 mg/m2 and docetaxel 40 mg/m2 on days 1, 8, 29,
and 36 with concurrent radiotherapy (40–60 Gy). All
patients achieved either partial response (73%) or stable
disease (27%). Of 20 patients who underwent resection
(91% of those enrolled), 19 had complete resections. With a
median follow-up of 32 months, seven patients (32%) had
relapsed, including five (71%) distantly. Of interest was a high
3-year survival rate (93%) in the 14 patients who achieved
disease downstaging with the preoperative regimen. Three-
year overall survival for the entire population was 66%. This
rate compares favorably with the 3-year survival rate of 38%
demonstrated in a separate phase II study of neoadjuvant
weekly carboplatin/paclitaxel with concurrent radiotherapy
in 38 patients with stage IIIA(N2) disease.32
The Southwest Oncology Group (SWOG) 8805 phase II
trial established the feasibility of a trimodality approach of
concurrent cisplatin/etoposide with radiotherapy followed
by surgery in 126 patients with stage IIIA(N2) NSCLC.33
The objective response rate to induction chemotherapy was
59%, with an 85% resectability rate for those patients
eligible for surgery, and a 3-year survival rate of 26%. ThatCopyright © Adis Data Information BV. Una
S80trial led to a US Intergroup trial RTOG0139 that aimed to
define further the benefit of surgery in resectable stage
IIIA(N2) disease, using a trimodal approach with concurrent
chemoradiation before surgery compared with chemoradia-
tion alone.34 A total of 429 patients were randomly assigned
to receive two cycles of cisplatin/etoposide given concur-
rently with radiation (45 Gy) followed by either surgery or
continued radiation to 61 Gy. Of the 429 patients, 396 (92%)
were able to continue to surgery or radiation after induction
chemoradiation. No significant difference in 5-year survival
rates was observed between the surgery and non-surgery
groups ( p¼ 0.24). A review of postsurgical deaths showed
that all but one followed a pneumonectomy, which suggests
that a trimodality approach may not be appropriate for
patients in whom pneumonectomy is planned.
UNRESECTABLE STAGE III NON-SMALL CELL
LUNG CANCER
The American Society of Clinical Oncology guidelines
for the treatment of unresectable stage III NSCLC
recommend combined modality therapy with platinum-
based chemotherapy and definitive thoracic radiation,
particularly for patients with good performance status.35
Recent clinical trials and a meta-analysis showed that
concurrent chemotherapy and radiotherapy (chemoradia-
tion) affords superior outcomes to sequential therapy.36–40
One of the first studies to demonstrate this difference was
conducted by the West Japan Lung Cancer Group, which
compared split-course radiotherapy concurrent with mito-
mycin, vindesine, and cisplatin with the sequential regimen
of mitomycin, vindesine, and cisplatin followed by non-split
course radiotherapy.36 Overall survival was significantly
longer in the concurrent arm (log-rank p¼ 0.04). Median
survival times were 16.5 months (concurrent) compared
with 13.3 months (sequential). Five-year survival rates
were 16 and 9%, respectively. Toxicities, particularly
myelosuppression and esophagitis, were more severe in the
concurrent arm. Similar percentages of patients in each
group experienced relapse; importantly, approximately 60%
of relapses involved distant sites.
Similarly, RTOG 9410, which compared two different
concurrent regimens (cisplatin and vinblastine withuthorized reproduction of this article is prohibited.
 2007 International Association for the Study of Lung Cancer
Journal of Thoracic Oncology * Volume 2, Number 6, Supplement 2, June 2007 Treatment for Locally Advanced NSCLCconventional radiotherapy or cisplatin and oral etoposide
with hyperfractionated radiotherapy) with a sequential
regimen of cisplatin and vinblastine followed by radiation,
demonstrated superior survival with conventional concur-
rent radiotherapy compared with the sequential regimen.37
Median survival times were 17.0 months compared with
14.6 months, and 4-year survival rates were 21% compared
with 12%, respectively. Acute non-hematological toxicities
were greater with concurrent therapy, and late toxicities
were similar.
Investigation of the role of full-dose chemotherapy as
induction or consolidation of concurrent chemoradiotherapy
seeks to augment control of distant micrometastases further.
When compared with sequential or concurrent regimens,
results from trials of induction regimens have been dis-
appointing. Three phase III trials failed to demonstrate a
significant clinical advantage for induction regimens when
compared with either sequential or concurrent regimens in
unresectable NSCLC.41–43
Consolidation was evaluated, along with sequential and
induction regimens in a phase II trial of 276 patients by the
American College of Radiology (ACR 427).44 In that trial,
each arm was not compared with each other but with a
reference standard. Sequential therapy consisted of two
cycles of full-dose paclitaxel (200 mg/m2) and carboplatin
(area under the curve [AUC] of 6) followed by daily
radiotherapy (63 Gy). The induction regimen consisted of
the same chemotherapy followed by concurrent chemor-
adiotherapy (weekly paclitaxel [45 mg/m2] and carboplatin
[AUC of 2] with daily radiotherapy [63 Gy]). The con-
solidation regimen consisted of the same concurrent
chemoradiotherapy followed by two cycles of full-dose
paclitaxel and carboplatin. Survival in each of the three arms
was compared with a median survival time of 13.7 months,
the RTOG reference standard at the time for sequential
therapy. The differences in median survival between each
arm and that of the reference standard were not statistically
significant. The median survival time in the consolidation
arm of 16.3 months is, however, intriguing and was the
longest among the three arms (compared with 12.7 months
with sequential and 13.0 months with induction.) Acute
toxicity was, however, more frequent in the consolidation
arm. The incidences of grade 3/4 esophagitis were 3% with
sequential, 19% with induction, and 28% with consolidation
( p< 0.0001). Grade 3/4 granulocytopenia occurred in 0, 16,
and 26% of patients, respectively, and pulmonary toxicity
occurred in 7, 4, and 16%, respectively.Copyright © Adis Data Information BV. Una
TABLE 3. Study designs of Southwest Oncology Group S90
SWOG 901947 S
No. of patients 50 8
Stage pIIIB p
Induction regimen Cisplatin–etoposide–RT C
Consolidation regimen Cisplatin–etoposide D
RT, radiation therapy.
 2007 International Association for the Study of Lung CancerConsolidation and induction were directly compared in
a randomized phase II trial of the Groupe Franc¸ais de
Pneumo-Cance´rologie.45 Patients (n¼ 133) with unresect-
able NSCLC received either induction or consolidation
with two cycles of cisplatin (80 mg/m2) and paclitaxel
(200 mg/m2). Concurrent chemoradiotherapy consisted of
cisplatin, vinorelbine and radiation to 66 Gy. The primary
endpoint was the response at the end of treatment, which for
induction was 55% and for consolidation was 48%. With a
26-month follow-up, survival appeared slightly better, but
not significantly, with induction compared with consolida-
tion (median 19.3 versus 16.9 months; 1-year 69 versus
60%; 2-year 47 versus 43%). Toxicities were generally
similar between the arms, although esophagitis occurred in
13% with consolidation compared with 6% with induction.
Together, these data demonstrate the need for a prospective,
phase III trial to evaluate consolidation regimens adequately.
In the interim, data from studies of consolidation therapy
have been promising. A phase III trial of the Groupe
Coope´rateur Multidisciplinaire en Oncologie compared
consolidation with observation after paclitaxel–carboplatin
concurrent chemoradiotherapy.46 Patients with unresectable
stage III disease (n¼ 71) received chemoradiotherapy with
weekly paclitaxel (45 mg/m2) and carboplatin (AUC 2)
concurrent with radiotherapy (60–66 Gy). Forty-one patients
with response or stable disease were randomly assigned to
consolidation with three 21-day cycles of paclitaxel (175 mg/
m2) and carboplatin (AUC 5) or observation. After a
minimum 3-year follow-up, overall survival, the primary
endpoint, was greater in the consolidation arm (3-year
survival rate 29.9% consolidation versus 10% for obser-
vation; p¼ 0.002). The trial demonstrates the difficulties in
delivering consolidation, with 30 patients (42%) not being
randomized as a result of progression, death, toxicity, refusal,
or protocol violation.
As the cisplatin/etoposide combination can be given at
full dose concurrent with radiation, this doublet is considered
the standard option for chemoradiotherapy protocols so as not
to compromise distant efficacy for local control. Two
sequential, non-randomized studies by the SWOG evaluated
consolidation with different regimens after cisplatin/
etoposide chemoradiotherapy, and a comparison allows
the evaluation of docetaxel as a consolidation agent
(Table 3).47–50 The first study (S9019) in 50 patients, all
with pathologically confirmed stage IIIB NSCLC, utilized
two cycles of cisplatin (50 mg/m2 a day on days 1 and 8) and
etoposide (50 mg/m2 a day on days 1–5) every 4 weeksuthorized reproduction of this article is prohibited.
19 and S9504 and Sekine et al.50 trials.
WOG 950448,49 Sekine et al.50
3 97
IIIB IIIA and IIIB
isplatin–etoposide–RT Cisplatin–vinorelbine–RT
ocetaxel 75 mg/m2 cycle 1
then 100 mg/m2 cycles 2–3
Docetaxel 60 mg/m2 q
3–4 weeks  3
S81
Rigas and Kelly Journal of Thoracic Oncology * Volume 2, Number 6, Supplement 2, June 2007concurrently with radiotherapy (61 Gy) followed by two more
cycles of the same chemotherapy.47 Median survival was 15
months, and the 5-year survival rate was 15%, promising
results in this advanced-stage population.
The second study (S9504) used the same staging,
eligibility criteria, and concurrent chemoradiotherapy as
S9019, but used docetaxel as the consolidation agent in 83
patients.48,49 Docetaxel was dosed at 75 mg/m2 in the first
cycle, then escalated to 100 mg/m2 for two additional cycles,
every 3 weeks, in the absence of toxicity. Median survival was
26 months, and the 5-year survival rate was 29%. These
survival benefits were unprecedented, and compare favorably
with results from S9019 (Figure 2). Nonetheless, approxi-
mately half of all patients in S9504 developed brain
metastases, which demonstrates the need for continued
efforts in treating the central nervous system. In comparing
toxicities between the two studies, no cases of grade 3–5
pneumonitis occurred in S9019. Although the incidence of
grade 3–5 radiation-induced pneumonitis was low in S9504
(7%), two deaths occurred. Grade 3/4 esophagitis occurred in
20% (S9019) and 17% (S9504) of patients. Grade 4
neutropenia was higher in S9504 compared with S9019
(54 versus 32%) and was associated to a greater extent with a
docetaxel dose of 100 mg/m2. That and other studies13,15
suggest that 75 mg/m2 is better tolerated without loss of
efficacy, and this lower dose has been incorporated into
several later NSCLC trials.
Additional data regarding docetaxel consolidation come
from two recent trials.50,51 In a phase II trial, 97 patients with
unresectable stage III NSCLC received docetaxel consolida-
tion (60 mg/m2 every 3–4 weeks) after concurrent chemor-
adiotherapy using cisplatin (80 mg/m2 day 1) and vinorelbine
(20 mg/m2 days 1 and 8) every 4 weeks for three cycles (Table
3).50 Of 93 evaluable patients, 52 (56%) had stage IIIB
disease. Only 37% of patients completed all three cycles of
docetaxel. Pneumonitis was the most common reason for
early discontinuation, and four patients died from this
complication. Nonetheless, the survival results are encoura-
ging, as the median survival was 30.4 months.
The second study is the phase III SWOG trial S0023.51
Although that trial aimed to evaluate the efficacy of gefitinib,
the design offers the chance to gain some information aboutCopyright © Adis Data Information BV. Una
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FIGURE 2. Comparison of long-term survival between
S9019 and S9504.47–49
Southwest Oncology Group 9504; Southwest Oncology Group
9019. Median follow-up 71 months.
S82consolidation docetaxel. Treatment involved chemoradiation
and consolidation using the S9504 regimen (cisplatin/
etoposide with concurrent radiotherapy and docetaxel
75 mg/m2 consolidation) followed by randomization to either
gefitinib or placebo. The trial was stopped with 620 patients
accrued after an unplanned analysis showed that a survival
benefit for gefitinib compared with placebo was not possible.
This preliminary analysis demonstrated an overall median
survival time of 19 months for the 571 eligible patients
enrolled. In the subset of patients who were then randomly
assigned to placebo or gefitinib after consolidation (42% of
the initially accrued population), the median survival times
were 29 months in 131 patients randomly assigned to placebo
compared with 19 months in the 124 patients randomly
assigned to gefitinib ( p¼ 0.08) With this docetaxel dose,
grade 4 neutropenia occurred in 35% of patients. The rate of
grade 3–5 radiation-induced pneumonitis was 8% in the
docetaxel consolidation portion of S0023, similar to the 7%
observed in S9504. These incidences are not higher than those
shown with sequential (13%) and concurrent (11%) therapies
as compared in RTOG 9410.37 In S0023, subset analysis
showed that radiation pneumonitis of grade 3 or higher was
significantly associated with the percentage of lung volume
receiving more than 20 Gy (V20) being greater than 35%; as
such, future trials will require V20 to be no greater than 35%.
The Hoosier Oncology Group (HOG) has also initiated a
phase III trial in this setting, LUN 01-24. Patients with
unresectable, stage IIIA–IIIB NSCLC received chemother-
apy with the same cisplatin/etoposide regimen utilized in
previous SWOG studies along with concurrent radiation of
59.4 Gy. Responding or stable patients were then randomly
assigned to either docetaxel 75 mg/m2 every 3 weeks for three
cycles or observation alone. Interim toxicity data from 73
patients randomly assigned to docetaxel consolidation were
presented in 2005.52 Similar to SWOG 9504 and S0023,
hematological toxicity was relatively common with this
regimen; grade 3/4 neutropenia occurred in 23% of patients
and 32% required granulocyte colony-stimulating factor
support. Grade 3/4 pneumonitis occurred in 9.6% of patients.
Treatment-related mortality was 5.5% (4/73), consistent with
the rate in the SWOG trials, which underscores the
importance of establishing whether docetaxel consolidation
significantly improves survival in a phase III trial so that the
risks and benefits can be clearly weighed.
FUTURE DIRECTIONS
Unanswered questions remain about definitive chemor-
adiotherapy, including the optimal chemotherapy agents;
dose, duration, and density of chemotherapy; clarifying the
role of consolidation; the integration of targeted agents,
identifying the proper radiation dose, schedule, and technique;
and finally, determining the ultimate role of surgery compared
with radiation as a local control modality. Ongoing studies are
focused on defining the role of epidermal growth factor
receptor inhibitors and antiangiogenesis agents in the stage III
setting (Table 4).53–56
Inconclusion, stageIIINSCLCisaheterogeneousdisease
that presents a management challenge to the clinician,uthorized reproduction of this article is prohibited.
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TABLE 4. Ongoing Trials with Novel Agents in Combination with Chemoradiation in Stage III Non-small Cell Lung
Cancer.
Study/Organization Population Novel Agent Regimen
Ongoing
SWOG 053353
Phase I/II
Unresectable stage IIIAN2 or B Bevacizumab (Avastin; Genentech,
South San Francisco, CA, USA)
Anti-VEGF monoclonal antibody
Bevacizumab introduced either
with (1) docetaxel
consolidation, (2) day 8
of PE/RT, or (3) day 1 of
PE/RT
SWOG 042954
Phase I
Poor-risk stage IIIA or IIIB Cetuximab (erbitux; ImClone
Systems, New York, NY,
USA and
Cetuximab with concurrent
RT with or without
concurrent docetaxel
Bristol-Myers Squibb,
New York, NY, USA)
CALGB 3040755 Unresectable stage IIIA or B Anti-EGFR monoclonal antibody Pemetrexed, carboplatin, and
RT with or without cetuximab
Dartmouth – DMS041056 Unresectable stage IIIA or B
stratified by stage, PS, and
weight loss
Erlotinib (Tarceva; Genentech,
South San Francisco, CA, USA)
EGFR TKI
Concurrent radiotherapy with
docetaxel and carboplatin
followed by erlotinib or
placebo
ChemoRT, chemoradiotherapy; EGFR, epidermal growth factor receptor; PE, cisplatin, etoposide; PS, performance status; RT, radiotherapy; TKI, tyrosine
kinase inhibitor; VEGF(R), vascular endothelial growth factor (receptor).
Journal of Thoracic Oncology * Volume 2, Number 6, Supplement 2, June 2007 Treatment for Locally Advanced NSCLCparticularly stages IIIA(N2) and unresectable disease. For
potentially resectable disease, neoadjuvant chemotherapy
decreases the risk of distant metastases and induces high rates
of response. A phase II study employing neoadjuvant
docetaxel/cisplatin suggested that this regimen is well
tolerated,doesnot increase perioperativemorbidity/mortality,
and may improve survival and reduce the risk of distant
and local relapse. Phase III randomized controlled trials are
needed to confirm the survival benefits of neoadjuvant
chemotherapy or induction chemoradiation followed by
surgical resection in this subset of patients with stage IIIA
NSCLC.
For patients with unresectable stage III NSCLC,
concurrent chemoradiation is the standard of care at the
present time for patients with good performance status, good
pulmonary function tests, and acceptable V20. Consolida-
tion therapy with docetaxel has shown clinical benefit in
several clinical trials, but the survival advantage must be
confirmed in a phase III trial, given the potential for
additional toxicity associated with the approach. Novel
molecular targeted agents should be integrated into the
treatment regimens; however, how best to accomplish this is
unclear and is under active investigation.
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